Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmos closes Israeli facility

This article was originally published in Scrip

Executive Summary

Pharmos is to end operations at its facility in Rehovot, Israel, and look for a partner to operate and fund its research programmes currently undertaken in the country. Pharmos will now manage the activities based in Israel from its headquarters in Iselin, New Jersey, but the senior management team of Dr Iris Alroy and Dr Arnon Aharon will remain in Rehovot as consultants for any further business developments and collaborations. Pharmos cut its workforce in Israel from 23 to eight people last November, as part of cost-reduction and restructuring plans after its net loss grew to $4.6 million for the second quarter of last year (ScripOnline, November 2nd, 2007). The company's net loss subsequently decreased in the fourth quarter of last year to $2.7 million but grew again to $3.6 million in the first quarter of this year. The facilities in Israel focus on a CB2 receptor selective library of compounds, including preclinical development of PRS-639,058 for neuropathic pain. The company has also completed a Phase IIa trial of its 3% diclofenac NanoEmulsion cream for the treatment of osteoarthritis pain.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts